Press

Nova Mentis Life Science Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment

Sep 15 • 3 min read

Quick Take: The psilocybin-based drug is designed to treat fragile X syndrome, the most common inherited cause of autism spectrum disorder. Nova Mentis Life Science Corp. (CSE: NOVA) (OTCQB: NMLSF), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has filed an application with the…

Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression

Sep 15 • 3 min read

Quick Take: The Phase 2a trial is a double blind, placebo-controlled study in patients with TRD. Each of the 3 parallel arms will enroll 31 patients at multiple locations. Patients will receive either placebo, a 30 mg dose, or a 60 mg dose of R-ketamine intravenously. Perception Neuroscience (Perception), an atai Life Sciences (NASDAQ: ATAI) biopharmaceutical company…

Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine

Sep 14 • 4 min read

Quick Take: Dr. Ilya Reznik, a renowned Neuropsychiatrist, joins Cannabics to lead in the development of psychedelic inspired medicines. Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that Dr. Ilya Reznik (MD), a renowned Neuropsychiatrist, has joined…

PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022

Sep 13 • 8 min read

Quick Take: For the rest of 2021, PharmaTher will focus on advancing three promising developments through FDA Phase 2 clinical studies PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to provide a product pipeline update and anticipated milestones for Q4-2021 and 2022 including ongoing FDA Phase 2 clinical study programs, microneedle…

Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds

Sep 10 • 3 min read

Quick Take: Hamilton Morris, creator of docu-series Hamilton’s Pharmacopeia, will engage with COMPASS as a full-time consultant, primarily working at their Discovery Center COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris, the research scientist and film-maker, as a…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435